will oversee the financial reconstruction of the Nuclear Power
Plant in Idaho for the purpose of setting up treatment facilities
for deep-seated inoperable brain tumors utilizing Boron Neutron Capture
Therapy. When finished and set into operation it will be the only privately
owned and operated nuclear medical facility in the world. The new facility
will also supply all of North America with Molly 99 radioactive isotopes
for research, medical and industrial use.
seven hundred and fifty million dollar project will also fund several
charitable projects including world wide indigent access, medical scholarships,
and grants to research and development in the field of Neutron Boron
Technologies. The new facilities will include a hospital, state of the
art laboratory, out patent clinic and living quarters.
going research shows promise for prostate, liver and breast cancer.
Boron Neutron Capture Therapy (BNCT) will impact some fifty to sixty
thousand lives a year world wide for deep-seated inoperable brain tumors.
is expected to take eighteen months to two years before the facilities
are fully operational. A world-class association of Neural Surgeon and
Nuclear Scientist in the field of BNCT will head up the IBT&IC Medical
Advisory Team. Mr. Willar will assume his new responsibilities in January
there is no cure for persons suffering from glioblastoma or other malignant
brain tumors. Over 7000 people die annually in the U.S. alone from this
disease and many others suffer substantial reduction in quality of life
from such brain tumors. The average life expectancy for persons diagnosed
with this disease is only 9 months! Over 70,000 new brain tumors of
all types are diagnosed each year in this country, most of which could
be effectively treated with BNCT.
Boron Neutron Capture Therapy, is a totally unique approach to cancer
treatment, currently perfected for brain tumors and melanoma, with possible
future applications to other cancers, such as breast, and prostate.
It uses an intravenous injection of boron, which concentrates in the
cancer cells rather than the normal cells. Neutrons from a nuclear reactor
are then applied; causing a lethal fission reaction that kills the boron
containing cancer cells but does not damage the normal cells.
initial concept of BNCT was developed in the 1950's by Boston neurosurgeon
Dr. William Sweet. However, the science was not yet advanced enough.
One of his students, Dr. Hiroshi Hatanaka, went on to develop BNCT further
in Japan where he was able to cure some patients with malignant brain
tumors, who went on to live normal lives for over 20 years. Building
on these results, US researchers began doing more work on BNCT in the
late 1980's, and treating the first human US patient in 1993.
clinical trials of BNCT have been done, using reactors at Brookhaven
National Laboratory, and MIT in Boston. So far the results of these
trials have been promising. After hundreds of laboratory animal tests,
16patients were treated at Brookhaven in 1995 and 1996.No patients had
any harmful side effects. The FDA considered this Phase I trial adequate
proof of safety and approved advancement to Phase II for proof of effectiveness,
currently in progress. At MIT, researchers are treating both glioblastoma
brain tumors and melanoma tumors with BNCT. So far their results are
promising. Patients are living longer with fewer side effects than with
November, 1997, a European BNCT Consortium began treating patients using
a reactor at Petten, Netherlands. In 1999, BNCT patient treatment began
at a reactor in Finland. In Studsvik, Sweden, a reactor is currently
being readied to begin BNCT patient treatments. Thailand is currently
developing a BNCT treatment program. While drugs are now available to
selectively carry boron into brain tumors and melanoma, there is further
research being done on developing drugs to selectively carry boron into
other cancers such as breast, prostate and lung. Once these are available
the same neutron beam could treat those cancers as well, with potentially
over a hundred thousand cancer patients a year benefiting from BNCT.
best reactor in the world for BNCT is the Power Burst Facility, (PBF)
located at the Idaho National Engineering and Environmental Laboratory,
(INEEL), of the US Department of Energy (DOE). This reactor has the
power to penetrate beyond the center of the brain as well as do the
entire treatment in 3 to 6 minutes compared to 40 minutes at Brookhaven
and several hours at MIT. In 1994 the Idaho Brain Tumor Center leased
the PBF reactor from DOE for 30 years, for the purpose of converting
it into a large scale brain tumor treatment center capable of treating
up to ten thousand patients a year. Although the original lease expired
before adequate private funding could be obtained, the DOE would still
like to see this humanitarian, "swords into plowshares" conversion
take place as soon as adequate funds are available. It is an outpatient
treatment, completed in a single day, requiring neither hospitalization
nor surgery. Our goal is to make this life saving treatment available
quickly to thousands of patients who are currently dying at the rate
of over 20 deaths a day!
Brain Tumor Center plans to convert this idle surplus nuclear
reactor to a state-of the-art cancer treatment center. Initially malignant
brain tumor patients will be treated from all over the country. As additional
drugs are developed to carry boron into other cancers the center will
treat patients with lung, prostate, pancreas and breast cancer as well.
Given that the Japanese, using a small, weak, reactor have been able
to get a 60% cure rate on tumors considered hopeless in the US, we expect
to be able to improve that to a better than 80% cure rate with the powerful
addition to benefiting cancer patients, this project has environmental
advantages. The DOE has a large supply of nuclear fuel for this reactor
in storage, which we can use at no cost. At the same time, by burning
up this fuel we save the government from having to otherwise bury it
in the ground or continue to store it at risk to the environment.
addition to funding the costs of converting the reactor to a cancer
treatment center, the foundation will also fund three additional related
funds for the treatment of indigent cancer patients who need BNCT treatment.
It is very important to the founder of IBT&IC that cancer patients
needing BNCT treatment receive it even if they have no insurance or
lack enough money to pay for the entire cost of treatment. In addition,
funds will be provided for transportation to the center, and also for
a family member to accompany the patient. Meals and lodging for patient
and family member will also be provided. Since IBT&IC will be the
only large scale source of BNCT treatment in this country for the next
decade or more, it is important that financial provisions for treating
indigent and uninsured patients be made early in the project.
funds for research in improving the technology of BNCT treatment, including
the development of new drugs that carry boron into other tumors, such
as breast, prostate, and lung cancer, to enable these cancers to also
be treated with BNCT. There are currently drugs available for brain
tumors, and melanoma. There is research going on in several universities
to develop new boron drugs to treat other tumors with BNCT. This research,
while expensive, holds the promise of greatly expanding the number of
cancer patients who can be treated with BNCT. The Foundation plans to
fund many research projects of scientists and doctors who have been
working on this development for years.
Foundation plans to promote education programs that inform the public,
patients and families, government officials, and health care professionals
about new developments in BNCT treatment of cancer patients. These programs
would include publications, scientific meetings, public forums, patient
support groups, magazine articles, and radio and television appearances
by BNCT experts. It is important for this information to be widely shared
to bring the benefits of BNCT to the public as soon as possible.
anticipate the need to raise at least one hundred fifty million dollars
to allow us to move forward quickly in achieving these goals. With hundreds
of thousands of cancer deaths each year we must move this technology
from the laboratory to the patients without delay.
and its associated non-profit foundation, (IBT&ICF) Idaho Brain
Tumor Cancer Foundation will have unrestricted use of the PBF reactor
during the lease. The only costs will be modification construction,
license fees, operating expenses and maintenance. The DOE will provide
site security. The PBF reactor has been maintained in an operational
ready status since 1986 with an annual budget of $2.5 million. The reactor
has ample fuel and additional supplies are available at INEEL.
mission statement for IBT&IC is two-fold: Provide the most comprehensive,
compassionate and cost-effective BNCT treatment facility in the world
for brain tumor patients, and provide a cost-effective reliable source
of medical isotopes for U.S. nuclear medicine.
over 70,000-brain tumor patients are diagnosed in the U.S. each year,
75% of whom could benefit from BNCT. The average cost of treatment per
patient is about $100,000. Since the PBF reactor produces a powerful
source of high quality neutrons, it will only require 3 minutes of exposure
time per patient to do the BNCT treatment. Therefore, with one shift
per day, IBT&IC can treat over 3,000 patients per year. With three
shifts per day, IBT&IC could treat 10,000 patients per year.
the operation of the PBF reactor, Mo99 will be produced in 6day cycles.
Production capacity will exceed one and a half times the current consumption
of Mo99 in the entire Western Hemisphere, and provide a revenue stream
of over $100 million. Other medical isotopes such as Iodine 131 (1-131)
and Xenon 133 (Xe-13~) are produced as a by-product of Mo99 production.
A biotech pharmaceutical company has contacted IBT&IC because they
project a need for $40-50 million in 1-131isotope. The end user market
for nuclear medicine in the U.S. today is estimated to be over $3 billion.
are only five reactors known in the world, which can produce the quality
of neutrons required for BNCT. The PBF reactor is the most powerful
and considered to be the best source.
International supplies 100% of the U.S. market for Mo99. Nordion has
announced plans to build replacement reactors in Canada at an estimated
cost of $140 million. Nordion has also indicated they win increase the
price of Mo99 by 300% over a few years. In January 1996,they increased
the price by 400.10, and increased another 400.10 in April 1997. That
is why we believe the U.S. market for Mo99 will be over $150 million
development calls for the company to develop two business lines. BNCT
cancer treatment has been discussed. There are 70,000 new brain tumor
patients diagnosed in the U.S. each year, at least 75% of whom could
benefit from BNCT.